every 8 or even every 6 h in CF patients.
Among the quinolones presently under investigation, ciprofloxacin has shown superior in vitro activity, especially against Pseudomonas aeruginosa (3, 22) . This microorganism, especially the mucoid strains, is extremely difficult to eliminate from the respiratory secretions of cystic fibrosis (CF) patients who are chronically colonized (19) . Ciprofloxacin, which can be administered orally, may become a useful drug for the treatment of this infection. In fact, several clinical trials are presently being done to study the clinical efficacy of ciprofloxacin in the treatment of acute pulmonary exacerbations in patients with CF (S. W. Bender p. 200, 1985) .
The pharmacokinetics of several antibiotics have been shown to be disturbed in CF patients. Increased clearance and altered volume of distribution for aminoglycosides and beta-lactam antibiotics have been described in patients with CF as compared with normal subjects or non-CF children (11, 12, 15, 25 ; L. Cliche, M. LeBel, and M. G. Bergeron, Can. J. Hosp. Pharm., in press). Conflicting results have been reported on impaired oral absorption of drugs in this population (6, 10, 17, 21) .
The purposes of this study were (i) to compare the single-dose and steady-state pharmacokinetics of ciprofloxacin in CF patients and in healthy volunteers (controls) and (ii) to determine the effect of ciprofloxacin therapy on bacterial counts (with special reference to P. aeruginosa) in the respiratory secretions of CF patients. * Corresponding author.
MATERIALS AND METHODS
Subjects. A total of 11 CF patients (7 males and 4 females; ages 19 to 25 years) and 12 healthy volunteers (6 males and 6 females; ages 19 to 25 years) gave their informed consent to participate in the study. Subject characteristics are described in Table 1 . The protocol was approved by the Centre Hospitalier de l'Universitd Laval Human Research Review and Pharmacology-Therapeutics committees. The diagnosis of CF was based on a compatible family and clinical history, abnormal sweat test, and pancreatic insufficiency or chronic pulmonary disease. All patients met these criteria. All patients except no. 11 had a good to excellent clinical evaluation score by the rating system of Shwachman and Kulczycki (23) . All subjects were judged to be otherwise healthy on the basis of a history, physical examination, chemistry profile, complete blood count, and urinalysis. Volunteers were determined to be not pregnant after direct latex agglutination pregnancy tests. The patients were studied during an infection-free period; they had stopped all prophylactic antimicrobial therapy (oral and inhalation) 5 days prior to the study. The CF patients were kept on pancreatic enzymes, multivitamins, and any other medications required by their disease ( Table 1) . The subjects had to restrain from any strenuous or athletic activity during the study period but were allowed to circulate around the clinical pharmacokinetic research unit. Alcoholic beverages and caffeine were withheld 24 h prior to the study and on day 1, 6, or 9.
Study design. On the morning of day 1 and following an overnight fast, each subject received a single 500-mg oral dose of ciprofloxacin (Miles Laboratories, Rexdale, Ontario, Canada) taken with 200 ml of drinking water. Starting on the morning of day 2 and continuing through day 5 for healthy the forearm after both the first and last doses. Only six CF patients (two females, four males) had skin blisters produced on the forearm after the last dose. Suction-induced skin blisters were produced by the slightly modified method of Hellum et al. (7) . In brief, a Plexiglas block with 10 bores (diameter, 8 mm) 'was strapped to the volar area of the forearm after the skin had been swabbed with 70% isopropanol. Controlled suction (-400 mm of Hg) was applied until semispherical blisters had been produced (1.5 to 2 h). The blister fluid was samnpled by puncture with a low-dead-space syringe (Micro-fine III; Becton Dickinson and Co., Rutherford, N.J.), and aspiration of 0. 10 to 0.15 ml of fluid was performed on one or two blisters, if needed. Each blister was sampled only once. The harvesting time sequence was 0.5, 1, 2, 2.5, 3, 4, 6, and 8 h after the first dose for healthy volunteers. After multiple doses, the blisters were punctured at '2, 3, 4, 6, 8, and 10 h for both groups.
Additional sampling was performed in the healthy volunteers at 1 and 24 h after the last dose. Respiratory secretions were obtained by expectoration in CF patients for ciprofloxacin concentration determinations at 1, 2, and 4 h after the first and last doses. Respiratory secretions were also collected for cultures and bacterial counts before the first dose and 2 h after the doses on days 5 and 9. On the last day, four patients had difficulty producing sputum, and in one of these a deep pharyngeal swab (Culturette II; Marion Scientific, Div. Marion Laboratories, Inc., Kansas City, Mo.) had to be used to extract secretions from her throat. Cultures and bacterial counts were repeated on respiratory secretions obtained 60 days after treatment.
Microbiology and susceptibility testing. Respiratory secretions were liquefied with equal volumes of Sputolysin (Calbiochem-Behring, La Jolla, Calif.) and cultured on MacConkey, Mannitol, blood, and chocolate agars. Microorganism identification was performed by standard bacteriological preparation involved protein precipitation with acetonitrile (1:2), followed by methylene chloride-2-propanol (90:10) extraction. The sensitivity limit of the assay was 0.06 ,ug of serum and blister fluid per ml. The coefficient of variation from day to day was <5.3%, and the serum and urine recoveries were 55 and 108%, respectively. Linear regression analysis of the standard calibration lines yielded a correlation coefficient of >0.999, indicating excellent linearity of the assay between 0.125 and 10.0 ,ug/ml. When compared with a microbiological assay of serum, the correlation coefficient was 0.922 (n = 58). Pharmacokinetic analysis. Pharmacokinetic analysis was performed by using model-independent methods. The elimination rate constant (kel) was calculated from the terminal exponential phase of semilogarithmic plots (4).
The area under the serum concentration-time curve (AUC) from time zero to time t (AUC,},) was calculated with conventional linear trapezoidal and extrapolation methods.
The apparent serum clearance (CLapp) of ciprofloxacin was estimated from the model-independent pharmacokinetics equation CLapp = dose/AUC> ,, where 0-t is 0 to infinity after a single dose and 0 to T after the last dose (here, T = 8 h). Although we previously used an absolute bioavailability value (f) of 70% to better estimate total clearance (14) 
RESULTS
Study groups. The demographic characteristics of both controls and CF patients are shown in Table 1 . On the morning of day 1, patient 6 chose not to participate in the study; we were unable to replace her. Although an attempt was made to select healthy volunteers with less-than-ideal body weight to match underweight CF patients, CF patients were 15 .9% lighter in weight than controls (P < 0.05).
Pharmacokinetics. Mean levels of ciprofloxacin in serum following the first (single) dose in CF patients and controls are shown in Fig. 1 , and the corresponding pharmacokinetic data are shown in Table 2 . Mean peak ciprofloxacin concentrations in serum were slightly higher in CF patients than in controls (2.84 + 0.63 versus 2.26 + 0.75 ,ug/ml, respectively) but did not reach the level of statistical significance. Although not visually apparent, the absorption phase was slower in CF patients, as shown by absorption constant values of 1.06 + 0.50 versus 2.79 ± 1.30 h-1 in CF and healthy subjects, respectively. 
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The elimination half-life of ciprofloxacin was decreased by a third in CF patients as compared with controls (2.62 ± 1.04 versus 3.93 ± 1.12 h, respectively; P < 0.01). This difference in mean half-life values cannot be visually observed in Fig. 1 , since representation of mean concentrations in serum vanish this difference (16) . Interestingly, we observed no statistically significant difference in apparent total clearance and between CF and healthy subjects. Furthermore, we normalized the apparent total clearance to lean body mass for each subject (Table 1) . Both apparent total clearances were fairly similar (945.3 versus 918.5 ml/min per 50 kg of lean body mass for CF and healthy subjects, respectively). The decreased half-life was the result of a diminished apparent volume of distribution (2.12 ± 0.75 versus 3.76 ± 0.90 liters/kg in CF patients and healthy volunteers, respectively; P < 0.001).
Although not completely comparable, steady-state ciprofloxacin levels in serum after the last dose for CF and control subjects (doses 22 and 13, respectively) are shown in Fig. 2 . As anticipated from pharmacokinetic theory, peak concentrations in serum for both CF and healthy subjects were higher (3.78 versus 2.84 and 3.51 versus 2.26 ,ug/ml, respectively) after the last dose than after the first dose ( Table 3) . As observed in healthy volunteers, the apparent total clearance of ciprofloxacin in CF patients showed a significant decrease after multiple doses. In contrast to healthy volunteers, no increase in half-life could be demonstrated in this patient population when single-dose and steady-state data were compared.
We performed an analysis of covariance with weight, body surface area, and lean body mass as covariables; these covariables were not statistically significant for any of the pharmacokinetic parameters, either for a single dose or for steady state, except for weight, which was a covariable (P < 0.02) for the time to maximum concentration of drug in serum after a single dose.
Mean peak concentrations of ciprofloxacin after a single dose in saliva were higher in controls than in CF patients (1.32 versus 1.01 ,ug/ml, respectively), but the difference was not statistically significant. At steady state, these peak levels in saliva were similar (1.57 jig/ml for normal volunteers and 1.51 pug/ml for CF patients). No statistically significant difference could be observed in peak levels in saliva between both groups. The ratios of the peak concentration in saliva to the simultaneous concentration in serum yielded remarkably constant values, except for controls after a single dose (0.78 + 0.36). The ratio after a single dose in CF patients was 0.49, and those at steady state were 0.55 and 0.53 in CF and healthy subjects, respectively.
Steady-state blister production was more erratic in CF patients; fewer blisters were obtained than in controls. Mean levels of ciprofloxacin in blister fluid for CF patients and controls are shown in Fig. 3 . The mean peak ciprofloxacin (2, 8, 27, 28 We also found in this study higher peak levels in serum for CF patients than for controls, although this difference was not significant. Sorgel and co-workers made similar observations when they speculated that the decreased bicarbonate secretion in CF patients, which could influence the ionization of ciprofloxacin in the gastrointestinal tract, makes ciprofloxacin more absorbable (Sorgel et al., Proc. 14th Int. Congr. Chemother.). Surprisingly, high ciprofloxacin concentrations in serum in CF patients may be the result of a combination of slower and more complete absorption and a smaller apparent volume of distribution than in controls. Blumer and co-workers showed that pancreatic enzymes had no effect on absorption, distribution, and elimination of ciprofloxacin (Blumer et al., Proc. 14th Int. Congr. Chemother.). According to blister fluid data, the distribution of ciprofloxacin in extracellular fluid did not seem to be affected in CF patients, as compared with normal volunteers.
The pharmacokinetic results presented here showed that ciprofloxacin should be administered every 8 or even every 6 h in CF patients. Ciprofloxacin induced a significant reduction in counts of P. aeruginosa, but this improvement was short-lived. We acknowledge the limitations of quantitative bacteriology in respiratory secretions obtained by expectoration, but we believe that this information is valuable in studies of the pharmacodynamic effects of antibacterial agents in clinical situations such as sputum colonization of CF patients. The secondary increase in bacterial counts observed in five patients and the development of five resistant strains are causes for concern. Others have recently observed bacterial resistance to ciprofloxacin after long-term oral administration ( 
